Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
From MaRDI portal
Publication:4670477
DOI10.1111/j.0006-341X.2000.01177.xzbMath1060.62547WikidataQ73326314 ScholiaQ73326314MaRDI QIDQ4670477
Ying-Kuen Cheung, Rick Chappell
Publication date: 22 April 2005
Published in: Biometrics (Search for Journal in Brave)
time-to-eventcontinual reassessment methodphase I trialdose limitinglate-onset toxicitieslikelihood-based design
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)
Related Items (34)
Target toxicity design for phase I dose-finding ⋮ Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials ⋮ Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment ⋮ Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes ⋮ Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial ⋮ A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering ⋮ Impact of different model structure and prior distribution in continual reassessment method ⋮ Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials ⋮ DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses ⋮ A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes ⋮ Stochastic approximation and modern model-based designs for dose-finding clinical trials ⋮ Dose finding with escalation with overdose control (EWOC) in cancer clinical trials ⋮ Bayesian models and decision algorithms for complex early phase clinical trials ⋮ The adaptive accelerated biased coin design for phase I clinical trials ⋮ Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Cumulative cohort design for dose-finding ⋮ Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent ⋮ Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials ⋮ Risk-Group-Specific Dose Finding Based on an Average Toxicity Score ⋮ Ethical issues in oncology biostatistics ⋮ A weighted zero-inflated Poisson model for estimation of recurrence of adenomas ⋮ Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities ⋮ Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach ⋮ Incoherent dose-escalation in phase I trials using the escalation with overdose control approach ⋮ Dynamic Comparison of Kaplan–Meier Proportions: Monitoring a Randomized Clinical Trial with a Long‐Term Binary Endpoint ⋮ Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology ⋮ Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials ⋮ On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance ⋮ A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method ⋮ A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes ⋮ Joint modelling of recurrence and progression of adenomas: a latent variable approach ⋮ A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients ⋮ Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Consistency of continual reassessment method under model misspecification
- Continual Reassessment Method: A Likelihood Approach
- A Random Walk Rule for Phase I Clinical Trials
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
This page was built for publication: Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
